MedPath

Janssen Biologics BV

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.janssen-biologics.nl

Clinical Trials

97

Active:94
Completed:2

Trial Phases

3 Phases

Phase 1:37
Phase 3:1
Phase 4:1

Drug Approvals

11

CIMA_AEMPS:5
NMPA:4
EMA:2

Drug Approvals

Golimumab Injection

Product Name
欣普尼
Approval Number
国药准字SJ20170050
Approval Date
Oct 10, 2024
NMPA

Golimumab Injection

Product Name
欣普尼
Approval Number
国药准字SJ20202003
Approval Date
Oct 10, 2024
NMPA

Infliximab for injection

Product Name
类克
Approval Number
国药准字SJ20171001
Approval Date
Jun 16, 2021
NMPA

Golimumab Injection

Product Name
欣普尼
Approval Number
S20170050
Approval Date
Dec 17, 2019
NMPA

Clinical Trials

Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials

Phase 1
37 (94.9%)
Phase 3
1 (2.6%)
Phase 4
1 (2.6%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.